Cemiplimab
Showing 101 - 115 of 115
Carcinoma, Basal Cell Trial in Worldwide (cemiplimab)
Active, not recruiting
- Carcinoma, Basal Cell
- cemiplimab
-
Phoenix, Arizona
- +70 more
Jun 30, 2022
Cutaneous Squamous Cell Carcinoma Trial (cemiplimab)
No longer available
- Cutaneous Squamous Cell Carcinoma
- cemiplimab
- (no location specified)
Jul 30, 2019
Cancer, Immune-related Adverse Event Trial in Durham (Medical chart review)
Enrolling by invitation
- Cancer
- Immune-related Adverse Event
- Medical chart review
-
Durham, North CarolinaDuke University Medical Center
Oct 20, 2023
EXploring Immune-related Adverse Events of Immune checkpoinT
Active, not recruiting
- Cancer
- +2 more
- Immune checkpoint inhibitor
-
Paris, France
- +1 more
Jul 5, 2023
Recurrent Squamous Cell Carcinoma of Head, Recurrent Squamous Cell Carcinoma of Neck, Metastatic Squamous Cell Carcinoma of Head
Completed
- Recurrent Squamous Cell Carcinoma of Head
- +3 more
-
Seoul, Korea, Republic of
- +5 more
Mar 17, 2020
Solid Cancer Trial in Chevy Chase, Easton, New York (Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or
Terminated
- Solid Cancer
- Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
-
Chevy Chase, Maryland
- +2 more
Jan 27, 2021
Oncology, NSCLC Stage IV, NSCLC, Stage III Trial in Drammen (UV1, Sagramostim, Anti-PD-1/PD-L1 treatment)
Recruiting
- Oncology
- +2 more
- UV1
- +2 more
-
Drammen, Viken, NorwayVestre Viken Health Trust
Aug 15, 2022
Advanced Cutaneous Squamous Cell Carcinoma Trial in Atlanta, Chicago, New York (Ruxolitinib)
Recruiting
- Advanced Cutaneous Squamous Cell Carcinoma
-
Atlanta, Georgia
- +2 more
Jun 28, 2022
Cancer, Immune System Disorder, Inflammatory Reaction Trial in Montreal
Recruiting
- Cancer
- +3 more
-
Montreal, Quebec, CanadaJewish General Hospital
Nov 30, 2021
Advanced Cancer, Advanced Malignancies Trial in Australia, Spain, United States (Cemiplimab, Hypofractionated radiotherapy,
Completed
- Advanced Cancer
- Advanced Malignancies
- Cemiplimab
- +7 more
-
Gilbert, Arizona
- +46 more
Jan 23, 2020
High-risk cSCC Treated With Surgery and Radiotherapy
Not yet recruiting
- Squamous Cell Carcinoma of the Skin
- Peripheral blood sampling in order to evaluate changes in the circulating immune population
- (no location specified)
Feb 15, 2022
CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term
Completed
- Paraneoplastic Syndromes
- This is a non-interventional study. We will collect clinical data exclusively, and will do so by reviewing all available patients clinical records.
-
Lyon, FranceCentre de référence des syndromes neurologiques paranéoplasiques
Jul 11, 2023
Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer Trial (biological, radiation, procedure)
Withdrawn
- Stage III Prostate Cancer
- +6 more
- Ipilimumab
- +3 more
- (no location specified)
Nov 7, 2019